Brugada syndrome (BrS), one of the most frequently diagnosed inherited 
arrhythmogenic syndromes, is responsible for more than 4% of all sudden deaths 
and at least 20% of sudden deaths in patients with structurally normal hearts. 
The sudden death is often the first symptom of BrS and appears most often 
already during the fourth decade of life of BrS patients. Implantation of 
cardioverter--defibrillator was proved to be the only effective treatment, i.e. 
prevention of the sudden death, in BrS. Thus, it is uniquely determined to be 
used in case of symptomatic BrS patients. On the contrary, the individual risk 
of life-threatening arrhythmias has to be thoroughly considered in case of 
asymptomatic BrS patients due to substantial side effects of implantation of 
cardioverter-defibrillator. This review first provides a summary of factors 
recommended for the risk stratification in BrS patients in 2005 including their 
support or rejection in the following studies. Subsequently, we focused on the 
most important risk factors newly suggested after 2005.